SCREaning of Advanced Liver Fibrosis Using Non-Invasive Tests in General Population
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-75
SponsorUniversity Hospital, Angers
About this trial
The main objective of the study is to evaluate the pertinence of initiating screening for advanced hepatic fibrosis after a FIB4 result \> 2.67 automatically calculated in the local laboratory and followed by a specialized hepatic evaluation.
Eligibility criteria
Qualifiers
Age between 18 and 70 years
Blood sample taken at a medical testing laboratory selected for the study.
Biology without high risk of false positive result for FIB4 (AST and ALT ≤ 300 IU/l ; Platelets ≥ 50 G/l and < 500 G/l.)
FIB4 > 2.67 after automatic calculation in the medical laboratory less than 3 months old
Disqualifiers
Ongoing specialized follow-up for a chronic liver disease
Difficulty understanding the French language
Pregnant women, breastfeeding or parturient women
Persons suspended from liberty by judicial or administrative decision
Trial design
Treatments tested in this trial
- FIB4
Treatment groups
502 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov